Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Abcuro, Inc.

Abcuro to Present Interim Phase 1 Data Evaluating Ulviprubart in Patients with T Cell Large Granular Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting
From Abcuro, Inc.
Via Business Wire
Abcuro Appoints George Eldridge as Chief Financial Officer
From Abcuro, Inc.
Via Business Wire
Abcuro Appoints Courtney Cupples as Chief Commercial Officer
From Abcuro, Inc.
Via Business Wire
Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting
From Abcuro, Inc.
Via Business Wire
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
From Abcuro, Inc.
Via Business Wire
Abcuro Announces Participation in Upcoming Investor Conferences
From Abcuro, Inc.
Via Business Wire
Abcuro Announces Participation in Upcoming Investor Conferences
From Abcuro, Inc.
Via Business Wire
Abcuro Appoints Sarah Boyce to its Board of Directors
From Abcuro, Inc.
Via Business Wire
Abcuro Completes Enrollment of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart for the Treatment of Inclusion Body Myositis
From Abcuro, Inc.
Via Business Wire
Abcuro Appoints Mark Pruzanski, M.D., as Chairman of its Board of Directors
From Abcuro, Inc.
Via Business Wire
Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis
From Abcuro, Inc.
Via Business Wire
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline
From Abcuro, Inc.
Via Business Wire
Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis
From Abcuro, Inc.
Via Business Wire
Abcuro Initiates Registrational Phase 2/3 Study of ABC008 for the Treatment of Inclusion Body Myositis
From Abcuro, Inc.
Via Business Wire
Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia
From Abcuro, Inc.
Via Business Wire
Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells
From Abcuro, Inc.
Via Business Wire
Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors
From Abcuro, Inc.
Via Business Wire
Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress
From Abcuro, Inc.
Via Business Wire
Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis
From Abcuro, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.